Lisa Maher is Head of the Viral Hepatitis Epidemiology and Prevention Program at the Kirby Institute for Infection and Immunity, National Health and Medical Research Council (NHMRC) Senior Research Fellow, and Professor in the Faculty of Medicine at UNSW Australia. She has international experience in research, surveillance, program development and service delivery with people who inject drugs, sex workers, PLHIV and marginalised youth and has provided technical advice to the WHO, UNAIDS, the World Bank, DFID, the Global Fund and AusAID. Professor Maher’s research focuses on the prevention of infectious disease in vulnerable populations and she has published more than 200 peer-reviewed papers. She has been the recipient of numerous awards and prizes, including the Australian Prime Minister’s Award for Excellence in Reducing the Harms of Drug Use in Australia and across the Asia/Pacific Region and the NHMRC’s Elizabeth Blackburn Fellowship (Public Health) for the highest ranked female applicant. In 2015, Professor Maher was awarded the Order of Australia for significant service to medicine in the field of epidemiology.
Society Memberships & Professional Activities:
Academy of the Social Sciences in Australia (ASSA); Australian Professional Society Alcohol and Other Drugs; Australasian Society for HIV Medicine (ASHM); Harm Reduction Australia International AIDS Society; International Centre for Science in Drug Policy.
Board and Committee Membership:
Centre for Social Research In Health Scientific Advisory Board, Communicable Diseases Network of Australia National Strategies HIV STI BBV Sub-Committee Hepatitis C Working Group (Chair); Harm Reduction Supplies Knowledge Hub Advisory Board; International HIV/AIDS Alliance Ukraine, Scientific Advisory Board; Lionel Murphy Foundation Board of Trustees; Lotus House Refuge Board of Management; Multicultural HIV and Hepatitis Service Advisory Group (Chair); National BBV and STI Surveillance Committee; NHMRC Centre for Research Excellence into Injecting Drug Use (CREIDU) Steering Committee; NHMRC Centre for Research Excellence (Immunisation in Under Studied and Special Risk Populations) Scientific Advisory Board; NSW Ministerial Advisory Council on Hepatitis (MACH); NSW Users and AIDS Association Expert Advisory Committee; NSW Ministry of Health Hepatitis B and Hepatitis C Strategies Implementation Committee; UNSW Emeritus Professor Committee; WHO Guidelines Development Working Groups – Prevention of Viral Hepatitis among People Who Inject Drugs; WHO WPRO Strategic Technical Advisory Committee on Viral Hepatitis.
Panels and Review:
Australian Research Council (ARC); Canadian Institutes of Health Research (CIHR); Economic and Social Research Council (UK); National Health and Medical Research Council (NHMRC); National Institutes for Health Research (UK); Wellcome Trust.